6185 Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6185 from our risk checks.
CanSino Biologics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$33.15 |
52 Week High | HK$36.85 |
52 Week Low | HK$14.80 |
Beta | 0.46 |
11 Month Change | 15.30% |
3 Month Change | 78.42% |
1 Year Change | 42.58% |
33 Year Change | -78.61% |
5 Year Change | n/a |
Change since IPO | -90.92% |
Recent News & Updates
Recent updates
Shareholder Returns
6185 | HK Biotechs | HK Market | |
---|---|---|---|
7D | 18.2% | 0.2% | 3.1% |
1Y | 42.6% | -4.8% | 19.6% |
Return vs Industry: 6185 exceeded the Hong Kong Biotechs industry which returned -4.8% over the past year.
Return vs Market: 6185 exceeded the Hong Kong Market which returned 19.6% over the past year.
Price Volatility
6185 volatility | |
---|---|
6185 Average Weekly Movement | 12.8% |
Biotechs Industry Average Movement | 10.8% |
Market Average Movement | 8.9% |
10% most volatile stocks in HK Market | 18.9% |
10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6185 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6185's weekly volatility (13%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
6185 fundamental statistics | |
---|---|
Market cap | HK$13.01b |
Earnings (TTM) | -HK$770.60m |
Revenue (TTM) | HK$801.01m |
10.2x
P/S Ratio-10.6x
P/E RatioIs 6185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6185 income statement (TTM) | |
---|---|
Revenue | CN¥748.53m |
Cost of Revenue | CN¥774.40m |
Gross Profit | -CN¥25.87m |
Other Expenses | CN¥694.25m |
Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.91 |
Gross Margin | -3.46% |
Net Profit Margin | -96.20% |
Debt/Equity Ratio | 41.3% |
How did 6185 perform over the long term?
See historical performance and comparison